GLP-1 Prior Authorization Guide: Requirements by Drug, Indication, and Payer (2025–2026)

GLP-1 receptor agonists are among the most prior-authorized drug classes in medicine — and among the most misunderstood from a coverage standpoint. The same molecule can require completely different documentation depending on whether it’s prescribed for Type 2 diabetes, weight management, or cardiovascular risk reduction. And for weight management, most patients hit a wall that has nothing to do with clinical criteria: their employer plan excludes the drug category entirely.

This guide covers all three pathways, major commercial payers, and Medicare.

Freshness notice: GLP-1 coverage policy is one of the fastest-moving areas in PBM management. Requirements below reflect policies as of mid-2026 (UHC 2026 P 1114-20, eff. 5/1/2026; Cigna IP0206, eff. 6/1/2026). Always verify against the payer’s current published clinical policy before submitting.

The Three PA Pathways

Before reviewing any criteria, establish which pathway applies:

The T2D and weight management pathways are structurally different even when the underlying molecule is the same. Mounjaro (tirzepatide for T2D) and Zepbound (tirzepatide for obesity) are the same drug at the same doses but require separate prescriptions and separate PAs under different benefit structures.

FDA-Approved GLP-1 and Dual Agonist Drugs

Type 2 Diabetes

Weight Management

Same Molecule, Different Coverage

The T2D PA for Ozempic does not transfer to Wegovy — they are separate NDCs, separate benefit categories, and often separate benefit pathways (pharmacy vs. medical benefit). Prescribing Ozempic off-label for weight loss will be denied.

CVS Caremark note (effective 7/1/2025): CVS Caremark removed Zepbound from its standard commercial formulary, naming Wegovy the preferred agent. Verify formulary placement before prescribing in plans administered by CVS Caremark.

Pathway 1 — Type 2 Diabetes

Common T2D PA Requirements

Diagnosis: Established Type 2 diabetes (ICD-10 E11.x). The confirmed T2DM diagnosis is typically the primary PA gate — most payers key off the diagnosis code rather than requiring a hard A1C floor for GLP-1 specifically.

Step therapy: Most commercial payers require metformin at maximally tolerated dose (with documented inadequate response, intolerance, or contraindication) before approving a GLP-1. Many plans also require one additional antidiabetic agent — commonly an SGLT2 inhibitor (empagliflozin, dapagliflozin), sulfonylurea (glipizide, glimepiride), or DPP-4 inhibitor (sitagliptin).

Mounjaro (tirzepatide) note: Some payer policies require trial and failure of a standard GLP-1 (semaglutide or dulaglutide) before approving tirzepatide. This varies by plan and is worth verifying before prescribing.

UnitedHealthcare — Type 2 Diabetes

UHC implemented PA requirements for GLP-1s in Medicare Advantage and Medicare Rx plans effective January 1, 2024. Key detail: members with a confirmed T2DM diagnosis on their member profile may bypass PA — the claim auto-processes. Confirm whether the patient’s profile reflects the T2D diagnosis before submitting a manual PA.

For commercial plans: established T2DM diagnosis + metformin step therapy + documented inadequate glycemic control. Authorization: 12 months.

Aetna — Type 2 Diabetes

Established T2DM diagnosis, metformin at maximally tolerated dose with documented inadequate response. Aetna’s clinical policy for GLP-1s in T2D is updated quarterly — pull the current CPB before submitting.

BlueCross / BCBS — Type 2 Diabetes

Criteria vary by regional plan. BCBS Massachusetts Policy 056 maintains a dedicated GLP-1-for-T2D policy with explicit step therapy through metformin. Most regional plans require the same T2DM diagnosis + metformin structure.

Cigna — Type 2 Diabetes

Established T2DM diagnosis, metformin at maximally tolerated dose. Cigna employer plan documents can modify national formulary criteria — verify the specific patient plan.

Medicare Part D — Type 2 Diabetes

GLP-1s for T2D are covered on virtually all Part D plans (Tier 2–5). PA is standard. Under OptumRx’s 2025 Premium Standard Formulary, Mounjaro, Ozempic, Rybelsus, and Trulicity are Tier 2 with PA and quantity limits.

Pathway 2 — Weight Management

The Coverage Exclusion Problem

Before reviewing PA criteria: most employer-sponsored plans exclude anti-obesity medications (AOMs) from coverage entirely. An AOM exclusion rider removes Wegovy, Zepbound, and Saxenda from the plan benefit regardless of BMI, comorbidities, or clinical need — no PA criteria exist because the benefit simply doesn’t exist.

By the numbers (KFF 2025 Employer Health Benefits Survey):

• 81% of firms with 200+ employees do NOT cover GLP-1s for weight loss
• 57% of firms with 5,000+ employees do NOT cover them (larger employers cover at higher rates)

This is a plan-document question, not a PA question. The fastest check: call the pharmacy benefits line and ask, “Does this plan cover anti-obesity medications — specifically Wegovy or Zepbound?” You’ll have an answer in under two minutes.

For the minority of plans that do cover AOMs:

Common Weight Management PA Requirements

BMI threshold (UHC 2026 P 1114-20 and Cigna IP0206, both verbatim):

• BMI ≥30 kg/m², OR
• BMI ≥27 kg/m² with at least one weight-related comorbidity

Qualifying comorbidities (Cigna IP0206 explicit list): hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, asthma, COPD, MASLD/NAFLD, PCOS, coronary artery disease.

Behavioral counseling prerequisite:

• Most payers require documented enrollment in a structured weight management program prior to or concurrent with AOM therapy
• Cigna: minimum 3 months of documented lifestyle modification program
• UHC: lifestyle modification required as adjunct; no minimum month count specified in the 2026 policy, but counseling documentation is expected

Quantity limits: 4 pens per 28-day supply for Wegovy and Zepbound (one weekly injection).

Authorization Duration and Renewal

Exact figures from primary-sourced policies (UHC 2026 P 1114-20, Cigna IP0206):

Renewal weight loss requirement:

• Wegovy: ≥5% body weight loss from baseline (UHC verbatim; Cigna: ≥5% after 1 year)
• Saxenda: ≥4% body weight loss from baseline (UHC)
• All: continued documented lifestyle modification

Document the patient’s baseline weight at time of prescription — not at the first office visit, not estimated. The renewal clock measures from that number.

UnitedHealthcare — Weight Management

Source: UHC PA Notification 2026 P 1114-20, effective 5/1/2026

BMI ≥30 or ≥27 + comorbidity (dyslipidemia, hypertension, T2D, sleep apnea). Lifestyle modification as adjunct required. Initial auth: 5 months (Wegovy), 6 months (Zepbound). Renewal at 12 months: ≥5% weight loss from baseline.

UHC-administered employer plans commonly carry AOM exclusion riders — verify coverage category before prescribing.

Aetna — Weight Management

BMI ≥30 or ≥27 + comorbidity. Documented dietary counseling and lifestyle intervention. Aetna requires structured weight management program documentation, not just a dietary recommendation noted in the chart. Renewal with documented clinical response.

BlueCross / BCBS — Weight Management

Highly variable by regional plan. Many employer-sponsored BCBS products carry AOM exclusion riders. FEP Blue covers some AOMs for members meeting BMI and comorbidity criteria — verify the current FEP formulary. Regional BCBS plans: pull the specific plan’s AOM or obesity clinical policy before assuming coverage.

Cigna — Weight Management

Source: Cigna IP0206, effective 6/1/2026

BMI ≥30 or ≥27 + comorbidity (explicit list includes HTN, T2D, dyslipidemia, OSA, CVD, OA, asthma, COPD, MASLD, PCOS, CAD). Minimum 3 months documented lifestyle modification. Initial auth: 8 months. Renewal: 12 months with ≥5% weight loss from baseline.

Individual employer plan documents can add requirements or exclude the AOM category entirely — verify the specific plan.

Humana — Weight Management

Standard BMI + comorbidity criteria. Humana has been expanding AOM coverage in its Medicare Advantage products faster than commercial. Commercial employer plan coverage varies — verify the specific plan benefit document.

Medicare Part D — Weight Management

Medicare Part D does not cover weight loss drugs. The Medicare Modernization Act categorical exclusion bars Part D coverage of drugs “for weight loss,” which CMS has confirmed applies to Wegovy and Zepbound when prescribed for obesity — regardless of BMI or comorbidities.

CMS proposed removing this exclusion in late 2024 but deliberately excluded the provision from the final 2026 rule (published April 2025). The statutory exclusion remains in effect.

The Medicare GLP-1 Bridge (CMMI demonstration program, running July 2026 – December 2027) provides limited access for qualifying Medicare patients at BMI ≥35, but this is a narrow pilot, not standard Part D coverage.

For Medicare patients, the CV risk indication below is the primary coverage pathway.

Pathway 3 — Cardiovascular Risk Reduction (Wegovy)

What Changed

The SELECT trial (Lincoff et al., NEJM 2023; n=17,604) showed semaglutide 2.4 mg reduced major adverse cardiovascular events by approximately 20% (MACE event 6.5% vs. 8.0% placebo; HR 0.80, 95% CI 0.72–0.90) in adults with established cardiovascular disease who were overweight or obese but did not have diabetes.

In March 2024, FDA approved a new indication for Wegovy: reduction of CV death, non-fatal MI, and non-fatal stroke in adults with established CVD and BMI ≥27. This created:

• A distinct commercial PA pathway separate from weight management
• The first Medicare Part D coverage pathway for Wegovy in the overweight/obese population (CMS guidance, March 2024: a drug approved for an additional non-weight-loss indication is a Part D drug for that indication)

CV Indication PA Criteria

Cigna IP0206 (verbatim): BMI ≥27 kg/m², established cardiovascular disease (prior MI, prior stroke — TIA excluded, or symptomatic PAD), age ≥45, without diabetes.

UHC 2026 P 1114-20 (verbatim): Prior myocardial infarction, ischemic or hemorrhagic stroke, or peripheral arterial disease.

Key differences from weight management pathway:

• BMI threshold: ≥27 only (no ≥30 floor required)
• No behavioral counseling trial prerequisite — the upfront documented lifestyle program requirement is absent. Lifestyle modification concurrent with treatment is expected but is not a gate
• Authorization: 12 months initial (longer than the 5–8 month weight management initial auth)
• AOM exclusion riders do not apply — the drug is being prescribed for CVD risk reduction, not weight loss

Medicare Coverage

CMS confirmed in March 2024 that Wegovy is coverable under Medicare Part D for the CV risk reduction indication. Coverage varies by individual Part D plan — Elevance, Kaiser, and CVS Health announced intent to add Wegovy for the CV indication; not universal.

Coverage routes through Part D (self-administered injectable), not Part B.

Practical Implications

For a Medicare patient with obesity and a prior MI: the weight management indication provides no Medicare coverage, but the CV risk reduction indication may open a Part D pathway. Document the CVD history explicitly and submit under the CV indication, not the obesity indication.

For commercial patients on plans with AOM exclusion riders: check whether the payer has carved out the CV indication from the exclusion rider. Several major payers have done this.

Tips for First-Pass Approval

For T2D:

1. Confirm whether the patient’s UHC profile has the T2DM diagnosis — if yes, PA may auto-process.
2. Document metformin trial with dates, dose, and reason for inadequate response or discontinuation.
3. Verify whether the plan requires a prior GLP-1 step before submitting Mounjaro.

For weight management:

1. Check benefit coverage before writing the Rx. Call the PBM. AOM exclusion = no PA path.
2. Document the structured weight management program: name, provider, dates, session count.
3. State BMI with measurement date. If using the ≥27 + comorbidity path, document the comorbidity explicitly in the PA — don’t reference a chart problem list.
4. Record the baseline weight at prescription initiation. The renewal gate measures from this.

For CV risk:

1. Document prior MI, stroke, or PAD history with dates.
2. State BMI ≥27.
3. Submit under the CV indication section of the Wegovy policy — not the obesity section.
4. On Medicare plans, confirm Wegovy is on formulary for the CV indication before submitting.

When the PA Fails

Sources

Primary policies referenced:

• UHC Pharmacy PA Notification — Weight Loss (2026 P 1114-20, eff. 5/1/2026)
• Cigna Coverage Position Criteria — Weight Loss GLP-1 Agonists (IP0206, eff. 6/1/2026)
• OptumRx 2025 Premium Standard Formulary
• KFF 2025 Employer Health Benefits Survey
• JAMA: Coverage and Prior Authorization for Semaglutide and Tirzepatide in Medicare Part D, Sept 2025 (PMC12397888)
• SELECT Trial: Lincoff et al., NEJM 2023
• CMS Coverage Guidance on GLP-1 Anti-Obesity Drugs (March 2024)

PA requirements update frequently. This guide was last reviewed June 2026. Always verify against each payer’s current published clinical policy before submitting.

Artificer Health automates prior authorization end-to-end — including AOM benefit eligibility checks before the prescription is written. Learn more at artificerhealth.com